Skip to main content
49°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Medmira
(TSV:
MIR
)
0.0950
UNCHANGED
Streaming Delayed Price
Updated: 9:32 AM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medmira
< Previous
1
2
Next >
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
April 17, 2025
Via
ACCESS Newswire
MedMira Reports Second Quarter Results FY2025
April 01, 2025
Via
ACCESS Newswire
MedMira Announces Partnership with MediGroup Physician Services in the United States
February 27, 2025
Via
ACCESS Newswire
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
February 25, 2025
Via
ACCESS Newswire
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
January 21, 2025
Via
ACCESS Newswire
MedMira Reports First Quarter Results FY2025
December 30, 2024
Via
ACCESSWIRE
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
November 28, 2024
Via
ACCESSWIRE
MedMira Announces the appointment of Vice President of Commercial Operations
October 03, 2024
Via
ACCESSWIRE
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
January 14, 2025
Via
ACCESSWIRE
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
January 09, 2025
Via
ACCESSWIRE
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
December 24, 2024
Via
ACCESSWIRE
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
August 13, 2024
Via
ACCESSWIRE
MedMira Reports Third Quarter Results FY2024
July 02, 2024
Via
ACCESSWIRE
MedMira Announces the Hire of Vice President of Business Development
April 30, 2024
Via
ACCESSWIRE
MedMira Reports Second Quarter Results FY2024
April 01, 2024
Via
ACCESSWIRE
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
February 01, 2024
Via
ACCESSWIRE
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
March 13, 2024
Via
ACCESSWIRE
Corporate Update on Clinical Evaluation of MedMira’s Products
February 01, 2024
Via
ACCESSWIRE
MedMira Reports First Quarter Results FY2024
December 29, 2023
Via
ACCESSWIRE
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
December 13, 2023
Via
ACCESSWIRE
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
November 28, 2023
Via
ACCESSWIRE
Update on MedMira’s Regulatory Path in Canada and the USA
September 27, 2023
Via
ACCESSWIRE
Progress Update on Securities
August 30, 2023
Via
ACCESSWIRE
MedMira Reports Third Quarter Results FY2023
June 29, 2023
Via
ACCESSWIRE
MedMira Reports Second Quarter Results FY2023
April 03, 2023
Via
ACCESSWIRE
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
March 14, 2023
Via
ACCESSWIRE
MedMira Enters into Partnership with Maternova for USA and Latin America
February 20, 2023
Via
ACCESSWIRE
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis
February 20, 2023
From
Maternova, Inc.
Via
Business Wire
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
January 11, 2023
Via
ACCESSWIRE
Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
January 03, 2023
Via
ACCESSWIRE
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
